NasdaqGM - Nasdaq Real Time Price USD

Lexeo Therapeutics, Inc. (LXEO)

3.4850

+0.1950

+(5.93%)

As of 2:27:12 PM EDT. Market Open.

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia (FA) cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned registrational study LX2006 registrational study expected to begin by early 2026; commencing enrollment in prospective natural history study, CLARITY-FA, in Q2 2025 to serve as concurrent external control Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently enrolling patients in Cohort 3; inter

GlobeNewswire 8 days ago

LXEO
+5.93%
Undervalued Penny Stocks To Consider In May 2025

The market has climbed 1.8% in the last 7 days and is up 9.5% over the last 12 months, with earnings expected to grow by 14% per annum over the next few years. In such a climate, identifying stocks with strong fundamentals can be key to uncovering hidden value. Though often seen as a relic of past trading days, penny stocks—typically representing smaller or newer companies—still offer potential for significant returns when backed by solid financials.

Simply Wall St. 18 days ago

OIS

LXEO
+5.93%
Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Research highlights AAV manufacturing optimization via Lexeo’s Sf9-baculovirus processNEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that new data supporting its AAV manufacturing approach will be presented at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 13-17, 2025 in New Orleans, L

GlobeNewswire 19 days ago

LXEO
+5.93%
Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

Participants with abnormal left ventricular mass index (LVMI) at baseline achieved 25% mean reduction in LVMI by 12 months or sooner Clinically meaningful improvements in majority of participants across cardiac biomarkers and functional measures All SUNRISE-FA participants achieved meaningful increases in frataxin expression at 3-months post treatment; 115% average cardiac frataxin expression increase in high dose cohort, demonstrating dose response Frataxin expression and LVMI improvement excee

GlobeNewswire last month

LXEO
+5.93%
Why Lexeo Therapeutics (LXEO) Skyrocketed on Monday?

We recently compiled a list of the 10 Small Firms Kick Off Monday with Strong Gains. In this article, we are going to take a look at where Lexeo Therapeutics, Inc. (NASDAQ:LXEO) stands against the other stocks with strong gains. Wall Street’s main indices kicked off Monday’s trading with a strong finish, ending in the […]

Insider Monkey last month

LXEO
+5.93%
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Additional alignment with FDA on LX2006 planned pivotal study including protein expression co-primary endpoint: based on improvements in LVMI across participants with abnormal LVMI at baseline, frataxin expression to be evaluated for any increase from baseline rather than numerical threshold Interim update from cohort 1 of LX2020 HEROIC-PKP2 Phase 1/2 trial: observed 71% and 115% increases in PKP2 protein expression in first two post-treatment biopsies; first participant evaluated 6-months after

GlobeNewswire last month

LXEO
+5.93%
Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases, today announced that R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 8:15 AM PT in San Francisco, California. The event will be webcast live under the News & Events tab in

GlobeNewswire 4 months ago

LXEO
+5.93%
Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced that Dr. Kyle Rasbach has been appointed Chief Financial Officer, effective immediately. Dr. Rasbach brings a wealth of life sciences experience to the company and joins ahead of multiple anticipated catalysts across its gene therap

GlobeNewswire 4 months ago

LXEO
+5.93%
Paula H. Cholmondeley Bought 96% More Shares In Lexeo Therapeutics

Potential Lexeo Therapeutics, Inc. ( NASDAQ:LXEO ) shareholders may wish to note that the Independent Director, Paula...

Simply Wall St. 5 months ago

LXEO
+5.93%
Here's Why We're Watching Lexeo Therapeutics' (NASDAQ:LXEO) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 5 months ago

LXEO
+5.93%
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints Received RMAT designation for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, potentially enabling expedited development and increased interaction with the FDA Completed enrollment of LX2006 SUNRISE-FA Phase 1/2 trial, with four participants

GlobeNewswire 6 months ago

LXEO
+5.93%
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Dose-dependent increase in neuroprotective APOE2 expression in all participants with ongoing durability at 12 months Consistent reductions across CSF tau biomarkers and tau PET in majority of participants LX1001 well tolerated across all dose cohorts with no reports of amyloid-related imaging abnormalities (ARIA) Company to host webcast today at 7:00 AM ET NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to p

GlobeNewswire 6 months ago

LXEO
+5.93%
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference

Late-breaking oral presentation to highlight safety and efficacy of LX1001 across four dose cohortsNEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced that interim data from the ongoing Phase 1/2 trial (NCT03634007) of LX1001 have been selected as a late-breaking oral presentation at

GlobeNewswire 6 months ago

LXEO
+5.93%
Lexeo Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced that Lexeo management will participate in corporate presentations and fireside chats at the following investor conferences: H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024 at 10:00 AM ET Baird

GlobeNewswire 8 months ago

LXEO
+5.93%
Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrated evidence of sustained and consistent treatment effect across multiple cardiac measures Recently initiated formal engagements with FDA on surrogate endpoints for LX2006 registrational study; expects to provide update by end of year Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently recruiti

GlobeNewswire 9 months ago

LXEO
+5.93%
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates

Cassava Sciences, Inc. (SAVA) and Lexeo Therapeutics (LXEO) are in the spotlight following updates.

Zacks 9 months ago

LXRX

SAVAW

KYTX
Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data

Interim data from an early-stage study shows that treatment with Lexeo's (LXEO) experimental gene therapy reduced signs of heart complications in patients with Friedreich's ataxia.

Zacks 9 months ago

LXEO
+5.93%

ARQT

CGEN
Why Lexeo Therapeutics Collapsed 26%, Sacrificing A Breakout In Bearish Fashion

Lexeo Therapeutics stock crashed Monday despite promising results for a gene therapy designed to treat heart problems of a genetic condition.

Investor's Business Daily 9 months ago

LXEO
+5.93%
Update: Lexeo Shares Tumble Despite 'Positive' Data in Trials of Gene Therapy Candidate for Cardiac Disorder

Update: Lexeo Shares Tumble Despite 'Positive' Data in Trials of Gene Therapy Candidate for Cardiac Disorder

PREMIUM
MT Newswires 9 months ago

LXEO
+5.93%
Lexeo Therapeutics Early Phase Trial for Friedreich Ataxia Cardiomyopathy Drug Shows Improvements in Cardiac Biomarkers

Lexeo Therapeutics Early Phase Trial for Friedreich Ataxia Cardiomyopathy Drug Shows Improvements in Cardiac Biomarkers

PREMIUM
MT Newswires 9 months ago

LXEO
+5.93%

Performance Overview

Return	LXEO	S&P 500 (^GSPC)
YTD	-47.04%	+0.80%
1-Year	-74.69%	+11.69%
3-Year	-63.32%	+51.96%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Lexeo Therapeutics, Inc. (LXEO)

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

Undervalued Penny Stocks To Consider In May 2025

Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

Why Lexeo Therapeutics (LXEO) Skyrocketed on Monday?

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

Paula H. Cholmondeley Bought 96% More Shares In Lexeo Therapeutics

Here's Why We're Watching Lexeo Therapeutics' (NASDAQ:LXEO) Cash Burn Situation

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates

Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data

Why Lexeo Therapeutics Collapsed 26%, Sacrificing A Breakout In Bearish Fashion

Update: Lexeo Shares Tumble Despite 'Positive' Data in Trials of Gene Therapy Candidate for Cardiac Disorder

Lexeo Therapeutics Early Phase Trial for Friedreich Ataxia Cardiomyopathy Drug Shows Improvements in Cardiac Biomarkers

Performance Overview